Wednesday, 29 January 2020

Transgenic Animals Market Size, Share Analysis, Strategies, Revenue and Forecasts to 2023

Market Scenario:
Transgenic animals or genetically modified (GM) animals have a foreign gene inserted into their DNA structure for various applications such as production of drugs, resistance to disease, and increasing yields. For instance, GM cows, sheep, and goats can produce growth hormone, insulin, and anticoagulants. The global transgenic animals market report by Market Research Future (MRFR) contains a compilation of drivers, threats, and opportunities which can work well for interested investors.
In 1997, Rosie (first transgenic cow) was produced with the aim of generating human protein-enriched milk. The milk was nutritionally balanced as compared to the natural bovine milk and was suitably exploited to meet the special nutritional requirements of the geriatric population and babies. Insulin, growth hormone, and anti-blood clotting factors are some of the products that can be effectively obtained from the milk of transgenic cows, sheep, or goats. Growing biotechnology sector followed by rising R&D expenses is estimated to be a major driver for the market growth during the forecast period. In 2016, the revenue generated by the emerging biotech industries across the globe was estimated to be around USD 139.4 billion. Moreover, increasing prevalence of cardiovascular diseases, diabetes, and other disorders along with the rising healthcare expenditures and growing awareness for the transgenic animals is boosting the market growth.
The market for transgenic animals is estimated to grow at an approximate CAGR of 8.60% from 2017 to 2023.
According to the World Health Organization in 2017, cardiovascular diseases were the main cause of the deaths across the globe. It was estimated that in 2015, approximately 17.7 million people died from cardiovascular diseases, representing 31% of all the global deaths. Of these deaths, an estimated 7.4 million were due to the coronary heart diseases and 6.7 million were due to stroke. However, stringent FDA policies followed by the high developmental cost and reluctance in the acceptance of transgenic products is estimated to restrain the market growth. The cost of producing a transgenic animal may range from USD 20,000 to USD 300,000.
Key players For Transgenic Animals Market
  • Cyagen Biosciences,
  • Charles River,
  • Creative-Biolabs,
  • TRANS GENIC INC.., Ltd.,
  • Sutter Instrument Company,
  • Bio-Rad Laboratories, Inc.,
  • Spinco Biotech Pvt Ltd.,
  • Abbott,
  • Thermo Fisher Scientific Inc.,
  • Sigma-Aldrich Co.,
Segmentation
The global transgenic animals market is segmented on the basis of product, techniques, consumables, application, model organisms, and end-user.
On the basis of the product, the market is categorized into PCR, gene gun, microinjections, electroporator, and others. The PCR segment is sub-segmented into real-time PCR, digital PCR systems, and others. On the basis of the techniques, the market is segmented into retrovirus-mediated gene transfer, embryonic stem cell-mediated gene transfer, DNA microinjection, and others.
On the basis of the consumables, the market is segmented into fluorescent probes, culture media, and others. On the basis of the application, the market is segmented into recombinant human proteins, monoclonal antibodies, xenotransplantation, and others.
On the basis of the model organisms, the market is segmented into mice, rabbit, cows, and others. On the basis of the end-user, the market is segmented into biotechnology industries, research organizations, academic institutes, and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Asthma Devices Market Forecasts by Industry Drivers, Regions Till 2023

Asthma Device Market Research Report: By Type (Inhalers, Nebulizers, Dry Powder Inhalers, Metered-Dose Inhalers, Mesh Nebulizers) By Technology (Manually Operated, Digitally Operated) By End Users (Hospital, Retail Pharmacies) – Global Forecast till 2023
Market Synopsis of Global Asthma Devices Market
Asthma is a chronic inflammatory lung disease that narrows the airways. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. Mostly, the symptoms associated with asthma are short-lived and can be easily treated. Asthma inhalers are medical devices which deliver medication into the body via the lungs, thereby, treating asthma and chronic obstructive pulmonary disease. Increasing prevalence of asthma is one of the major drivers for the market growth. According to the World Health Organization in 2017, approximately 235 million people suffered from asthma. Moreover, it was estimated that in 2015, the disease killed approximately 383 million patients around the globe. Additionally, rising healthcare expenditures and increasing awareness fuel the market growth. However, long treatment procedures and low per capita income followed by lack of favorable reimbursement policies in the developing countries will restrain the market growth during the forecast period.
The global asthma devices market size is expected to grow at an approximate CAGR of 4.3% during the forecast period. 
Segmentation
The global asthma devices market is segmented on the basis of type, technology, and end users.
On the basis of the type, the market is segmented into inhalers, nebulizers, and others. The inhalers segment is sub-segmented into metered-dose inhalers and dry powder inhalers. The metered-dose inhalers segment, by inhalers, is further categorized into standard pressurized metered-dose inhalers, breath-activated pressurized metered-dose inhalers, metered-dose inhalers with a spacer, and others. The nebulizers segment is sub-segmented into compressor nebulizers, ultrasonic nebulizers, mesh nebulizers, and others.
On the basis of technology, the market is segmented into manually operated inhaler devices, digitally operated inhaler devices, and others.
On the basis of end users, the market is segmented into hospital, clinics, retail pharmacies, and others.
Regional Analysis 
The Americas dominate the global asthma devices market owing to a well-developed healthcare sector and huge patient population for asthma diseases. According to the Centres for Disease Control and Prevention, in 2015, approximately, 7.8% of the total population in the U.S. was identified for the presence of asthma. Moreover, changing lifestyle and increasing healthcare expenditure fuels the market growth. Additionally, the presence of global players like Merck & Co., Inc. and Baxter, and others boost market growth during the forecast period. 
Europe is the second largest asthma devices market owing to a well-developed healthcare infrastructure and huge patient population. Moreover, government support for research & development and rising healthcare expenditures fuel the market growth. According to a study published in the Asthma Research and Practice journal in 2017, the yearly estimated cost for all the asthmatics per patient is about USD 1,900. Additionally, the presence of the developed economies like the U.K, Germany, and France within the region boosts the market growth. 
Asia Pacific is the fastest growing region in the global market due to the presence of a huge patient population and continuously developing economies like India and China. According to a study of the Indian Chest Society in 2015, 300 million people suffered from asthma worldwide and about a tenth of its share is in India. Moreover, as per the Indian Brand Equity Foundation in 2017, the Indian healthcare sector is one of the fastest growing industries and is expected to advance at a CAGR of 22.8% and reach USD 280 billion by 2020. Moreover, favorable government policies like reduced excise and customs duty followed by the exemptions in service tax along boosts the market growth. 
On the other hand, the Middle East & Africa holds the least share of the global asthma devices market due to the presence of poor economy, especially within the African region. The absence of the developed healthcare sector and stringent government policies restrain the market growth within the African region. Majority of the market within the region is held by the Middle East due to huge healthcare expenditures. 
Key players for global asthma devices market
GlaxoSmithKline plc. (Europe), Merck & Co., Inc. (U.S.), 3M (U.S.), Aristopharma Ltd. (Asia Pacific), SRS PHARMACEUTICALS PVT. LTD. (Asia Pacific), AstraZeneca (Europe), Baxter. (U.S.), Boehringer Ingelheim GmbH (Europe), Koninklijke Philips N.V. (Europe), and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Anaplasmosis Treatment Market Trend, Industry Overview, Competitive Analysis and Foreseen by 2023


Anaplasmosis is a zoonotic disease affecting dogs, cats, livestock, wildlife, and human. It is highly unlikely that a person will contract anaplasmosis from pets directly, but pets could bring ticks with the infection into home, posing a risk to the family. If a pet is diagnosed with anaplasmosis, precautionary measures to reduce the risk of infection. The disease is known as human granulocytic anaplasmosis (HGA) in people, canine granulocytic anaplasmosis in dogs, equine granulocytic anaplasmosis in horses, and tick-borne fever in ruminants.

Favorable government policies for research and the presence of a large number of players in the global anaplasmosis treatment market are the key factors driving the growth of the market during the forecast period.

The frequency of reported cases of anaplasmosis is highest among people over 40 years of age. A compromised immune system such as patients undergoing cancer treatments, advanced human immunodeficiency virus infection, prior organ transplants may increase the risk of the severe outcome. Individuals working or spending time in known tick habitats such as the zoo, animal rearing, and farms may be at increased risk for infection.

Although anaplasmosis infections can occur during any time of the year, the majority of cases reported to the CDC have an illness onset during the summer months and peaks in the months of June and July. This period is the season for the proliferation of nymphal black-legged ticks that bite humans and may transmit the pathogen.

The Global anaplasmosis treatment market size is expected to grow at a CAGR of approximately 6.3% during the forecast period 2017-2023.

Key Players
Some of key the players in the global anaplasmosis treatment market are Wyeth Pharmaceuticals (U.S.), Merck Sharp & Dohme (France), Boehringer Ingelheim (France), Bristol-Myers Squibb and Company (U.S.), Glaxosmithkline Inc. (U.S.) Aventis Pharma (Canada), Mylan Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals (Israel), Shire (U.S.), Procter & Gamble, (U.S.), Duramed Pharmaceuticals (U.S.), Takeda Pharmaceuticals (Japan), Ciba Vision (Germany)  Novopharm (Canada), and others.

Segmentation
The anaplasmosis treatment market is segmented on the basis of species, diagnosis, application, treatment, and end-users.
On the basis of the species, the market is segmented into Deer tick (Ixodes scapularis), western black-legged tick (Ixodes pacificus), Anaplasmosis phagocytophilum or A. platys
On the basis of the diagnosis, the market is segmented into enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody (IFA), and polymerase chain reaction (PCR) tests
On the basis of the application, the market is segmented into humans, pets, livestock, wildlife, and others 
On the basis of the treatment, the market is segmented into antibiotics, vaccines, and others. The antibiotics can be further classified as doxycycline, tetracyclines, chlortetracycline, oxytetracycline, rolitetracycline, minocycline, and others.
On the basis of the end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies, and others.
Regional Analysis
The global anaplasmosis treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East, and Africa.
The American anaplasmosis treatment is the largest market across the globe owing to the high investment in various private and government-funded research, and increased spending on pharmaceutical industry. This condition is commonly reported from the upper midwestern and northeastern United States. the black-legged tick (Ixodes scapularis) is responsible for transmission of A. phagocytophilum in the upper Midwest and northeastern U.S. These tick species also transmit the agents of Lyme disease (Borrelia burgdorferi) and babesiosis (Babesia species). Moreover, the human co-infections with these organisms have occasionally been reported. Anaplasmosis treatment is now being controlled in North America due to numerous veterinary control measures such as routine screening and vaccination of domestic livestock.
European market is projected to hold the second largest share of the global anaplasmosis treatment market as due to the eradication of these disease from Europe. Although some clinical cases of human granulocytic anaplasmosis have been reported in Europe, mostly from Slovenia, Sweden, and Poland, most cases have occurred in the United States. According to the U.S. National Library of Medicine, the prevalence of Ixodes ricinus ticks in Europe is 3% which is as higher than the United States. The average prevalence rate of A. phagocytophilum infection among humans in Europe was 6.2% in 2010 and is estimated to reach up to 21% by 2020.
The Asia Pacific and the Middle Eastern region are expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the healthcare sector.
Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report 

Posted by at No comments:
Labels:

Bone Biopsy Market Segmentation and Analysis by Recent Trends and Growth Prospects by Regions to 2023

Market Scenario
Bone Biopsy market growth is driven by increasing prevalence of chronic diseases such as Chronic Kidney Disease (CKD) and demand new diagnostic services. Additionally, increasing research and development activities, technological advancements to identify the causes and risk factors associated with osteopenia and osteoporosis also fuel the market growth of global market.
The Global Bone Biopsy Market Size is expected to grow at a CAGR of 5.7% during the forecast period.
According to the World Health Organisation (WHO), cancer was the leading cause of the total number of deaths globally as of 2015 and was responsible for 8.8 million deaths. The most common causal agents identified are cigarettes, cigars, pipes and chewing tobacco. According to the Cancer Research U.K, looking at the lifestyle factors responsible, it has been found that out of 3 diagnosed cases, 1 may be linked to smoking.
Bone biopsy is performed to diagnose various bone disorders such as bone cancer, bone infection, osteoporosis and chronic kidney disease. Nowadays, biopsy procedure has received great importance in oncology as one of the promising methods in cancer diagnostics. The demand for needle biopsy is found to be increasing from last few years.
Key Players in the Global Bone Biopsy Market     
  • C R Bard (U.S.),
  • Becton,
  • Dickinson and Company (U.S.),
  • Braun Melsungen AG,
  • Hologic, Inc. (U.S.),
  • Cook Medical (U.S.),
  • Devicor Medical Products Inc. (U.S.),
  • Argon Medical Inc. (U.S.)
Segmentation      
The global bone biopsy market is segmented on the basis of type, indication and end user.
On the basis of the component, market is segmented into needle biopsy and open biopsy.
On the basis of the application, the market is segmented into bone cancer, bone infection, chronic kidney disease, osteoporosis, and others
On the basis of the end user, the market is segmented into hospital & clinics, surgical centers, diagnostic centers, and others.
Regional Analysis
America holds the first position in the bone biopsy market owing to the rising prevalence of cancer in the U.S. and increasing demand for new cancer diagnostic and treatment services. In Americas, North America is the largest market owing to the presence of key players in healthcare diagnostic industry. The prevalence of osteoporosis is found to be higher in the population over 35 years for age. Changing lifestyle, emphasis on fitness and exercise, and overall development of medical device industry also accelerate the growth of the market.
Europe is the second largest market for bone biopsy. In Europe, there is an increasing demand for advanced bone biopsy devices, and extensive research and development activities by clinical research and academic institutes for cancer diagnosis and treatment. Germany is the largest market followed by France. The market in Germany is driven by increasing demand for specialty care services.
The market in Asia Pacific is expected to grow at the fastest pace and is driven by the high prevalence of chronic disease such as kidney disease, obesity, diabetes and other. India, China, and Japan are major contributors to the growth of the market. This growth is attributed to an increasing demand of technologically advanced medical devices in diagnostic centers and availability of highly qualified medical professional dedicated to research in oncology. Additionally, rising healthcare expenditure and extensive growth of medical device industry also influence the use of medical devices for diagnosis of various diseases such as osteoporosis, diabetes, cancer, and others.
The Middle East & Africa also show a steady rise in the market owing to low technology penetration and increasing awareness about cancer treatment. In the Middle East & Africa, United Arab Emirates captures the largest market share for bone biopsy owing to the availability of better healthcare infrastructure and a wide scope for research. In Africa, the market also shows a positive growth owing to development of healthcare system in African countries, and increasing demand for primary care services.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

The Refsum Disease Market Grows Incredibly; Confirms MRFR Unleashing Industry Prognostications Up To 2023

Refsum Disease Market Information: by Type (Adult Refsum Disease, Others), Diagnosis (Physical, Molecular Genetic Examination, Prenatal Screening, Enzyme Analysis, Other Testing), Treatment (Medical, Surgical Care), End User - Global forecast till 2023
Refsum disease is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene that metabolizes phytanic acid. According to the U.S. National Library of Medicine, more than 90 % cases of refsum disease result from the mutations in PHYH gene, and the remaining cases are caused by mutations in a gene PEX7 gene.
Notably, increasing awareness among people is the key factor driving the refsum disease treatment market. According to the National Organization of Rare Diseases, the age of onset of refsum disorder varies greatly. The disease can occur at any time from early childhood to nearly 50 years of age, but in most cases will have appeared by age 20. Males and females are equally affected in numbers.
Various other push factors such as increasing awareness among people, increasing government assistance, improving regulatory framework, and rising funding and reimbursement continuously contributing to the growth of the global refsum disease market.
Despite these drivers, there are some issues associated with refsum disease market. Some of the challenges in research and development, and poor healthcare system in low and middle-income countries may hinder the growth of the market to some extent.
It is estimated that the refsum disease market is expected to grow at a CAGR 5.4% during the forecast period of 2019-2023.
Key Players
  • Fresenius Kabi,
  • Braun Medical Inc.,
  • Medline Industries, Inc.,
  • Illumina, Inc.,
  • Igenomix,
  • Ceuta Healthcare Limited,
  • Cochlear Ltd.,
  • Cook,
  • Sonova,
  • William Demant Holding A/S,
  • Nurotron Biotechnology Co. Ltd.,
  • Agilent Technologies,
  • Bio-Rad Laboratories, Inc.,
Segmentation
The global refsum disease market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into adult refsum disease, and others. The adult refsum disease is further segmented into adult refsum disease 1, and adult refsum disease 2.
On the basis of the treatment, the market is classified as medical care, and surgical care. The medical care is further segmented into diet, plasmapheresis, and medication. The sub-segments of medication include keratolytics, and others.
On the basis of the diagnosis, the market is classified into physical examination, molecular genetic testing, prenatal screening tests, preimplantation genetic diagnosis, enzyme analysis, anosmia testing, and others. The molecular genetic testing is further segmented into genotyping, sequencing of gene, amplification or hybridization method, methylation-specific techniques, and others. The prenatal screening tests are further segmented into ultrasound, blood tests, chorionic villus sampling (CVS), amniocentesis, and others.
On the basis of the end-user, the market is segmented into hospital, clinics, diagnostic centers, research & academic institutes, and others.
Regional Analysis
The Asia Pacific is the fastest growing refsum disease market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Americas dominate the refsum disease market owing to the rising awareness among people and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the refsum disease market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in healthcare is likely to drive the market of the European region.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

The Evans Syndrome Market World Leading Key Players Revenue, Share, Analysis and Estimation Till 2023

Market Synopsis of the Global Evans Syndrome Market
Evans syndrome Market Information: by diagnosis (blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry), treatment (Splenectomy, Pharmacologic, Biologic therapy, Stem Cell), end user – Global forecast till 2023
Notably, growing public awareness is the key factor driving the Evans syndrome market. Nowadays, people are becoming more aware of the different types of autoimmune disorders. Government and other different organizations have started educating people about hygiene and diseases through seminars, and conferences. People are becoming more aware and conscious of the diseases. Thus, increasing awareness has provided a push to the growth of the market.
According to the Centers for Disease Control & Prevention, autoimmune disorder is the third most common category of disease in the United States after heart disease and cancer. It is reported that it affects approximately 5%–8% of the population i.e. 14–22 million persons.
The severity and symptoms of Evans syndrome vary greatly from one person to another. Some patients with Evans syndrome may first show the high destruction of red blood cells (RBCs), known as anemia, and others may first show low levels of platelets, known as thrombocytopenia. Low levels of white blood cells (WBSs), known as neutropenia, is less common in individuals with Evans syndrome than thrombocytopenia or anemia.
It is estimated that the Evans Syndrome Treatment Market is expected to grow at a CAGR 10.2% during the forecast period of 2017-2023.
Various other factors such as increasing incidents of autoimmune disorders, increasing government assistance, improving regulatory framework, increasing automation of laboratories and rising funding and reimbursement are continuously contributing to the growth of the global Evans syndrome market.
Despite these drivers, there are some issues associated with Evans syndrome market. Some of the challenges in research and development, side-effects of treatment, the presence of misbranded and spurious drugs, and poor healthcare system in low and middle-income countries, may hinder the growth of the market to an extent.
Evans syndrome (ES), is an autoimmune disorder characterized by the subsequent or simultaneous development of autoimmune hemolytic anemia, and immune thrombocytopenia. It is classified as primary or secondary based on its association with others diseases, such as primary antiphospholipid syndrome, systemic lupus erythematous (SLE), Sjögren syndrome, Hodgkin lymphoma, IgA deficiency, and chronic lymphocytic leukemia.
Key Players
Some of key the players in the global Evans syndrome market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, BD, ChemoMetec A/S, and Others.
Segmentation
The global Evans syndrome market is segmented on the basis of diagnosis, treatment, and distribution channels.
On the basis of the diagnosis, the market is classified as blood test, bone marrow biopsy, antibody assays, computed tomography (CT) scan, flow cytometry of double-negative T cells, and others. The blood test is further segmented into complete blood count (CBC), and direct antiglobulin test.
On the basis of the treatment, the market is classified as pharmacologic therapy, splenectomy,
Biologic therapy, stem cell transplantation, and others. The pharmacologic therapy is further segmented into Prednisone and intravenous immunoglobulin (IVIg) therapy. The biologic therapy is segmented into Rituximab and others.
On the basis of the distribution channel, the market is segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies, and others.
Regional Analysis
The Americas dominate the Evans syndrome market owing to the rising awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in the Evans syndrome market. It is expected that the support provided by the government bodies for research & development and improvement in reimbursement policies in the healthcare is likely to drive the market of Europe region.
Asia Pacific is the fastest growing Evans syndrome market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to lack of technical knowledge and poor medical facilities.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Uterine Sarcoma Market 2019 - Shares, Revenue, Analysis and Forecasts Till 2023

Uterine Sarcoma Market research report, type (LMS, undifferentiated sarcoma), diagnosis (sampling & testing, imaging tests), treatment (surgery, radiation therapy, hormone therapy), end users (Hospitals, Research Organization) - global forecast till 2023
Market Scenario:
Sarcomas are the tumours of the mesenchymal tissues like bone, muscle, connective tissue, cartilage and fat. Uterine sarcoma is a rare type of cancer which starts in the muscle and supporting tissues of the uterus. Exposure to the X-rays increases the risk for uterine sarcoma. Unusual vaginal bleeding, spotting, or discharge are some of the common symptoms for the disease. Increasing prevalence of the uterine sarcoma and growing female geriatric population are the major drivers for the market growth during the forecast period, 2017-2023. In 2017, according to the American Cancer Society, 4,910 new cases of uterine sarcomas were reported in the U.S. Moreover, according to the World Bank, the female population which aged over 65 years rose from 316.27 billion to 347.25 billion in 2016.
Additionally, rising healthcare expenditures and increasing awareness regarding women health is expected to boost the market growth. However, high cost of treatment and related side effects are the factors that can restrain the market growth. Chemotherapy is extensively exploited for the therapeutics of the uterine sarcoma. Some of the side effects of the chemotherapy are inclusive of hair loss, anemia, reduced fertility, and others.
The global uterine sarcoma market share is expected to grow at an approximate CAGR of 8.5% from 2017 to 2023.
Key players
  • Pfizer Inc.
  • Intas Pharmaceuticals Ltd.
  • FMC Corporation
  • Sun Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.
  • General Electric Company
  • Koninklijke Philips N.V.
  • Siemens Healthcare Private Limited
Segmentation
The global uterine sarcoma market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the treatment, the market is segmented into surgery, radiotherapy, chemotherapy, hormone therapy, and others. The surgery segment is sub-segmented into bilateral salpingo-oophorectomy, hysterectomy, and others. The chemotherapy segment is sub-segmented into dacarbazine, docetaxel, doxorubicin, and others. The hormone therapy segment is sub segmented into progestins, aromatase inhibitors, and others.
On the basis of the type, the market is segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others.
On the basis of the diagnosis, the market is categorised into sampling & testing, imaging tests, and others. The sampling & testing segmented is sub-segmented into endometrial biopsy, dilation and curettage, cystoscopy and proctoscopy, and others. The imaging tests segment is sub segmented into transvaginal ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography scan, and others.
On the basis of end users, the market is segmented into hospitals & clinics, academic institutes research organization, and others.
Regional Analysis
Asia Pacific region is also regarded to be the fastest growing market. Increasing awareness for women health and growing healthcare sector are the major drivers for the market growth within the region. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was one of the fastest growing industries in India and is expected to advance at a CAGR of 22.87% from 2015-2020.
America dominates the global uterine sarcoma market owing to increasing adoption of new technologies and huge patient population. Additionally, rising healthcare expenditure and presence of a developed healthcare sector within the region fuels the market growth.
Europe is the second largest market for uterine sarcoma owing to rising research and development in healthcare sector and huge patient population.  By region, Europe is divided into Western Europe and Eastern Europe. The presence of developed economies like France, Germany, Italy have made the Western Europe to lead the market within the region. On the other hand, Eastern Europe is the fastest growing region in Europe.
The Middle East & Africa has the least share in the global uterine sarcoma market due to presence of poor economies and stringent government policies, especially in the African region. Majority of the market of Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the economies like Saudi Arabia, Kuwait and Qatar within the region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)